×
About 33,518 results

ALLMedicine™ Pancreatic Cancer Center

Research & Reviews  11,431 results

Enhancing the cost-effectiveness of surgical care in pancreatic cancer: a systematic re...
https://doi.org/10.1016/j.hpb.2021.11.004
HPB : the Official Journal of the International Hepato Pa... Karunakaran M, Jonnada PK et. al.

Dec 2nd, 2021 - Clinical pathways (CP) based on Enhanced recovery after surgery (ERAS®) are increasingly utilised in patients undergoing pancreatoduodenectomy (PD). This systematic review aimed to compare the impact of CPs versus conventional care (CC) on peri-PD...

The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer ...
https://doi.org/10.21873/anticanres.15416
Anticancer Research; Ruff JP, Kretz AL et. al.

Dec 2nd, 2021 - This study was designed to analyse the effects of the novel, orally bioavailable CDK9-inhibitor Atuveciclib (BAY 1143572) in combination with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) on pancreatic ductal adenocarcinoma (PDA...

Intravenous Administration of Dehydroxymethylepoxyquinomicin With Polymer Enhances the ...
https://doi.org/10.21873/anticanres.15419
Anticancer Research; Fujisaki H, Nakano Y et. al.

Dec 2nd, 2021 - Pancreatic cancer, which exhibits resistance to cytotoxic and molecular targeted drugs, has an extremely poor prognosis. Nuclear factor-κB (NF-κB) is constitutively activated in many pancreatic cancer cases. Although the NF-κB inhibitor dehydroxym...

Evaluation of Erastin as a Therapeutic Agent Under Hypoxic Conditions in Pancreatic Can...
https://doi.org/10.21873/anticanres.15424
Anticancer Research; Owada S, Endo H et. al.

Dec 2nd, 2021 - In pancreatic cancer tissues, hypoxic areas exist due to poor blood flow. Attenuation of the pharmacological efficacy of existing anticancer drugs in these hypoxic areas necessitates the search for novel anticancer compounds. We aimed to determine...

Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer pa...
https://doi.org/10.1016/j.ejso.2021.11.116
European Journal of Surgical Oncology : the Journal of Th... Aaltonen P, Carpén O et. al.

Dec 1st, 2021 - Whilst treatment modalities for pancreatic cancer patients have evolved in recent years, their impact on outcomes remains relatively unexamined on a national scale. We aimed to analyse changes in overall survival and trends in surgical and oncolog...

see more →

Guidelines  24 results

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0017
Journal of the National Comprehensive Cancer Network : JN... Tempero MA, Malafa MP et. al.

Apr 13th, 2021 - Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provi...

SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058005
Clinical & Translational Oncology : Official Publication ... Gómez-España MA, Montes AF et. al.

Mar 5th, 2021 - Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have a profound knowledge about the molecular landscape of these neoplasms and this has allowed new therapeutic options. Surgery i...

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021,...
https://doi.org/10.6004/jnccn.2021.0001
Journal of the National Comprehensive Cancer Network : JN... Daly MB, Pal T et. al.

Jan 7th, 2021 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and r...

International consensus guidelines on surveillance for pancreatic cancer in chronic pan...
https://doi.org/10.1016/j.pan.2020.05.011
Pancreatology : Official Journal of the International Ass... Greenhalf W, Lévy P et. al.

Jul 7th, 2020 - Patients with chronic pancreatitis (CP) have an increased risk of pancreatic cancer. We present the international consensus guidelines for surveillance of pancreatic cancer in CP. The international group evaluated 10 statements generated from evid...

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and P...
https://doi.org/10.6004/jnccn.2020.0017
Journal of the National Comprehensive Cancer Network : JN... Daly MB, Pilarski R et. al.

Apr 8th, 2020 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are dia...

see more →

Drugs  54 results see all →

Clinicaltrials.gov  723 results

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04222413

Nov 25th, 2021 - Background: Metarrestin is a first-in-class investigational agent targeting the peri-nucleolar compartment (PNC), a marker of genome organization associated with metastasis. Preclinical studies have shown that metarrestin effectively suppresses me...

Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT03307564

Nov 24th, 2021 - Pancreatic ductal adenocarcinoma is now the third leading cause of cancer-related death, with a devastating 5-year overall survival (OS) rate of nearly 8%, despite having the 12th most common incidence of all malignancies in the United States. One...

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT05132504

Nov 24th, 2021 - This is a Phase II trial of NEOADJUVANT FOLFIRINOX CHEMOTHERAPY WITH PEMBROLIZUMAB followed by SURGERY and Adjuvant PEMBROLIZUMAB for Patients with LOCALIZED, RESECTABLE Adenocarcinoma of the pancreas. Investigators hypothesize that appropriately ...

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT02207465

Nov 23rd, 2021 - The investigators hypothesize that intensification of local therapy will lead to improvements in local control and survival in patients with unresectable and borderline resectable pancreatic cancer. We propose to do this by combining nab-paclitaxe...

Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT04082455

Nov 23rd, 2021 - The carbon dose of 60-67.5GyE in 15 fractions was delivered to clinical target volume (CTV). The dose limiting toxicity (DLT) was defined as CTCAE grade 3 or higher of non-hematological toxicity (G3). The acute and late toxicities, overall surviva...

see more →

News  1,133 results

Increased Risk of Stroke in Cancer Patients and Survivors
https://www.medscape.com/viewarticle/963095

Nov 16th, 2021 - Takeaway A meta-analysis indicates that individuals living with and beyond certain cancers may have an increased risk of stroke. Why this matters Findings suggest that assessment of cardiovascular risk should be a part of cancer survivorship care,...

Tidutamab Shows Early Tolerability, Active Immune Profile in Advanced Neuroendocrine Tumors
https://www.onclive.com/view/tidutamab-shows-early-tolerability-active-immune-profile-in-advanced-neuroendocrine-tumors

Nov 15th, 2021 - Tidutamab (previously XmAb18087) was found to be well tolerated with a best overall response of stable disease in patients with advanced, well-differentiated neuroendocrine tumors (NETs) of pancreatic, gastrointestinal (GI), lung and undetermined ...

Dr. Soares on the Standard of Care in Metastatic Pancreatic Cancer
https://www.onclive.com/view/dr-soares-on-the-standard-of-care-in-metastatic-pancreatic-cancer

Nov 11th, 2021 - Heloisa P. Soares, MD, PhD, medical oncologist, assistant professor, Huntsman Cancer Institute, University of Utah, discusses the standard of care in metastatic pancreatic cancer. Currently, in the treatment landscape for locally advanced metasta...

Saif Shares Insights on Single-Agent PARP Inhibitors and Combination Therapies for Pancreatic Cancer
https://www.onclive.com/view/saif-shares-insights-on-single-agent-parp-inhibitors-and-combination-therapies-for-pancreatic-cancer

Nov 10th, 2021 - Studies evaluating PARP inhibitors, metabolic agents, and stroma-targeting strategies are contributing to advances in treatment for patients with pancreatic cancer, according to Wasif M. Saif, MD. As strategies veer toward precision medicine appro...

Dr. Saif on the Rationale to Utilize PARP Inhibitors in BRCA+ Pancreatic Cancer
https://www.onclive.com/view/dr-saif-on-the-rationale-to-utilize-parp-inhibitors-in-brca-pancreatic-cancer

Nov 10th, 2021 - Wasif M. Saif, MD, MBBS, deputy physician in chief, director of medical oncology, Northwell Health Cancer Institute, professor of medical oncology, Donald and Barbara Zucker School of Medicine, Hofstra/Northwell, discusses the rationale to utilize...

see more →

Patient Education  42 results see all →